These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32406603)

  • 1. Role of non-inflammatory factors in intestinal fibrosis.
    Zhao JF; Ling FM; Li JR; Chen YD; Huang L; Zhu LR
    J Dig Dis; 2020 Jun; 21(6):315-318. PubMed ID: 32406603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we prevent, reduce or reverse intestinal fibrosis in IBD?
    Latella G; Sferra R; Speca S; Vetuschi A; Gaudio E
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1283-304. PubMed ID: 23740440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of initiation and progression of intestinal fibrosis in IBD.
    Latella G; Di Gregorio J; Flati V; Rieder F; Lawrance IC
    Scand J Gastroenterol; 2015 Jan; 50(1):53-65. PubMed ID: 25523556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic modulation during intestinal fibrosis.
    Bos S; Laukens D
    J Dig Dis; 2020 Jun; 21(6):319-325. PubMed ID: 32406133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Disease and Perspectives for Therapeutic Implication.
    Bettenworth D; Rieder F
    Dig Dis; 2017; 35(1-2):25-31. PubMed ID: 28147352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease.
    Lovisa S; Genovese G; Danese S
    J Crohns Colitis; 2019 Apr; 13(5):659-668. PubMed ID: 30520951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy.
    Wang Y; Huang B; Jin T; Ocansey DKW; Jiang J; Mao F
    Front Immunol; 2022; 13():835005. PubMed ID: 35370998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mechanisms and clinical trial endpoints in intestinal fibrosis.
    Wang J; Lin S; Brown JM; van Wagoner D; Fiocchi C; Rieder F
    Immunol Rev; 2021 Jul; 302(1):211-227. PubMed ID: 33993489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation.
    Shimshoni E; Yablecovitch D; Baram L; Dotan I; Sagi I
    Gut; 2015 Mar; 64(3):367-72. PubMed ID: 25416065
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms of tissue remodeling in inflammatory bowel disease.
    Rieder F; Fiocchi C
    Dig Dis; 2013; 31(2):186-93. PubMed ID: 24030223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Features of intestinal lesions in the clinical course of inflammatory bowel diseases.
    Vetuschi A; Latella G; Pompili S; Gaudio E; Sferra R
    Ital J Anat Embryol; 2014; 119(3):286-303. PubMed ID: 26749690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and Molecular Mechanisms of Intestinal Fibrosis.
    Wu X; Lin X; Tan J; Liu Z; He J; Hu F; Wang Y; Chen M; Liu F; Mao R
    Gut Liver; 2023 May; 17(3):360-374. PubMed ID: 36896620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cytokine and immune responses in intestinal fibrosis.
    Yang B; Zhang G; Elias M; Zhu Y; Wang J
    J Dig Dis; 2020 Jun; 21(6):308-314. PubMed ID: 32410365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal fibrosis in IBD--a dynamic, multifactorial process.
    Rieder F; Fiocchi C
    Nat Rev Gastroenterol Hepatol; 2009 Apr; 6(4):228-35. PubMed ID: 19347014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal Cell Regulation of Intestinal Inflammatory Fibrosis.
    Yang W; Yu T; Cong Y
    Cell Mol Gastroenterol Hepatol; 2024; 17(5):703-711. PubMed ID: 38246590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Multiple Faces of Integrin-ECM Interactions in Inflammatory Bowel Disease.
    Garlatti V; Lovisa S; Danese S; Vetrano S
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD.
    Latella G; Rogler G; Bamias G; Breynaert C; Florholmen J; Pellino G; Reif S; Speca S; Lawrance IC
    J Crohns Colitis; 2014 Oct; 8(10):1147-65. PubMed ID: 24731838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severity of local inflammation does not impact development of fibrosis in mouse models of intestinal fibrosis.
    Hünerwadel A; Fagagnini S; Rogler G; Lutz C; Jaeger SU; Mamie C; Weder B; Ruiz PA; Hausmann M
    Sci Rep; 2018 Oct; 8(1):15182. PubMed ID: 30315190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPAR-γ with its anti-inflammatory and anti-fibrotic action could be an effective therapeutic target in IBD.
    Vetuschi A; Pompili S; Gaudio E; Latella G; Sferra R
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8839-8848. PubMed ID: 30575926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative assessment of intestinal stiffness and associations with fibrosis in human inflammatory bowel disease.
    Stewart DC; Berrie D; Li J; Liu X; Rickerson C; Mkoji D; Iqbal A; Tan S; Doty AL; Glover SC; Simmons CS
    PLoS One; 2018; 13(7):e0200377. PubMed ID: 29995938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.